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ABSTRACT 
Objective: The aim of this study was to enhance the dissolution of a poorly water-soluble drug, lornoxicam by fabricating as nanoparticles using 
anti-solvent precipitation method and to investigate the effect of stabilizers on the particle size. 
Methods: Nanocrystals of lornoxicam were prepared by precipitation method using water as antisolvent with stabilizers, β cyclodextrin, and PVP-
K30. Characterization of the unmilled lornoxicam powder and nanocrystals was carried out by the Fourier transform infrared spectroscopy (FTIR), 
scanning electron microscopy (SEM), differential scanning calorimetry (DSC), X-ray diffraction (XRD) and dissolution tester.  
Results: Nano range (130-280 nm) particles were obtained which was confirmed by particle size analyzer. The dissolution of the drug 
nanoparticles (LBCD, LPVP) was carried out in pH 6.8 phosphate buffer solution and was significantly higher and almost complete compared with 
the pure drug. According to DSC, X-ray diffraction analysis, the nanocrystals were still in crystalline state after the preparation procedure. By 
reducing the particle size, the in vitro dissolution of lornoxicam was complete, 100% within 1 hr compared to the pure drug which showed an 
incomplete release of 37.35±1.09%. 
Conclusion: Nanocrystals of lornoxicam was prepared and nanocrystal technology can be an effective tool for enhancing the solubility of poorly 
soluble drugs 
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Lornoxicam (chlortenoxicam) a congener of tenoxicam, is a BCS class 
II drug. It is a new nonsteroidal anti-inflammatory drug (NSAID) of 
the oxicam class with analgesic, anti-inflammatory, and antipyretic 
properties, and is available as oral and parenteral formulations. Its 
analgesic activity is comparable to that of opioids. It is a potent 
analgesic with excellent anti-inflammatory properties in a range of 
painful and/or inflammatory conditions, including postoperative 
pain and RA [1, 2]. In spite of this wide spectrum of pharmacological 
properties, its use in the pharmaceutical field is limited by its low 
water solubility. Lornoxicam is extremely hydrophobic in nature and 
has poor absorption in the gastrointestinal tract. This highlights the 
need for an improved formulation for lornoxicam with enhanced 
dissolution so that its absorption can be greatly enhanced. 
Formulation techniques like emulsions, microemulsions, liquid 
solids, inclusion complexes, liposomes and polymeric architectures 
(micelles, microspheres etc) have been employed extensively but 
these processes often experience problems such as poor physical 
stability, difficulty in scale up and inability to achieve high drug 
loading; issues which have so far prevented them from being widely 
adopted for wider use [3-5]. 
A classical approach for poorly soluble drugs is nanonization, means the 
production of drug nanoparticles with a mean particle size below 1 μm; 
nanometric dimensions. The principle is to increase the dissolution 
velocity and saturation solubility by enlarging the surface area of the 
drug which is governed by Noyes-Whitney theory. Nanonization can 
result in improved drug solubility and pharmacokinetics, and it might 
also decrease systemic side-effects [6]. Pharmaceutical nanocrystals, an 
application of crystal engineering is gaining popularity in this context. 
Nanocrystals are nanoparticles with a crystalline character having the 
ability to increase the saturation solubility and the dissolution velocity by 
virtue of surface area enlargement [7]. They contain 100% drug without 
any matrix material or polymer. 
Stabilisers such as surfactants or polymers are located on the 
surface of the nanocrystals [8]. Theoretically, they are 100% 
crystalline materials but during processing, they may sometimes get 
converted to an amorphous state and these partly amorphous 
nanostructures are also called nanocrystals or sometimes 
“nanocrystals in amorphous state” [9, 10]. 
Nanocrystals are typically composed of drugs and stabilizers 
(polymers or surfactants) with average diameters less than 1 µm, 
and they can be prepared by bottom-up (Antisolvent precipitation) 
or top-down (media milling, high-pressure homogenization and etc.) 
methods, combination methods and chemical synthesis [11, 12]. 
Nanocrystal products showed their therapeutic applicability through 
various routes of administration like oral [13], ocular [14], 
parenteral [15], dermal [16], and pulmonary [17] as well as for 
targeted delivery [18]. 
Despite the advantages of drug nanocrystals, nanocrystals are 
essentially thermodynamically unstable systems [19], so the major 
drawback is the stability issue, which is the critical aspect in 
ensuring safety and efficacy of drug products [20]. As the vander 
waals forces become dominant at nanoscale, they cause the drug 
nanoparticles to aggregate [3, 21] For this reason, available 
stabilizers are added to reduce the Gibbs free energy of the system, 
in which they decrease interface tension and inhibit excess crystal 
growth and particle aggregation due to Ostwald ripening by 
electrostatic or steric stabilization [22]. As a result, a careful 
selection of appropriate stabilizers is critical. 
The present work of formulating lornoxicam as drug nanoparticles 
by anti-solvent precipitation method has significant importance to 
enhance its dissolution. The effect of stabilizer on the formation of 
nanocrystals has been investigated regarding particle size, 
crystallinity, and dissolution. 
MATERIALS AND METHODS 
Lornoxicam was obtained as a gift sample from Aristo 
Pharmaceuticals Pvt Ltd, Hyd. Cyclodextrin and PVP-K30 were 
obtained from SD Fine-Chem Ltd, Mumbai. DMSO was obtained from 
Qualigens Fine Chemicals, Mumbai.  
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Preparation of lornoxicam nanocrystals 
Anti-solvent precipitation method [23-25] was used for the 
preparation. Owing to the very poor solubility of lornoxicam, 
DMSO (Dimethyl sulfoxide) was selected as solvent and water as 
antisolvent. Pure lornoxicam was dissolved in DMSO and the 
solution was passed through 0.45 membrane filter for filtering out 
possible particulate impurities. 300 mg of stabilizing agent (βCD, 
PVP) was dissolved in 100 ml of double distilled water in another 
beaker. Stabilizer solution was used as antisolvent. This stabilizer 
solution was placed under propeller mixer which was rotating at a 
constant speed of 1000 rpm. Then drug solution was injected into 
stabilizer with the help of 25 mm syringe by dropwise. Stirring 
was continued for 2 h, during the process the drug gets 
precipitated from the solution. Then it is centrifuged for 10 min at 
a speed of 10000 rpm at 4 °C using REMI centrifuge. After 
centrifugation, the preparation was suspended in 50 ml of distilled 
water and sonicated for 10 min. After sonication, the suspension 
was filtered through 0.2 μ filter using vacuum filtration and 
thoroughly washed with distilled water, and then dried at 70 °C for 
24 h. The prepared nanocrystals LBCD (lornoxicam nanocrystals 
using β CD) and LPVP (lornoxicam nanocrystals using PVP) were 
further characterized. 
Characterization of nanoparticles 
Fourier transform infrared spectroscopy (FTIR) 
Infrared spectra of samples were recorded using FTIR spectrometer 
(A213T46, Schimadzu) to evaluate the molecular status of pure 
lornoxicam and prepared nanocrystals. About 3-4 mg sample was 
directly placed on the stage of the spectrometer and scanned from 
4000-400 cm-1.  
Scanning electron microscopy (SEM) 
The morphology of nano-sized crystals was examined using a 
scanning electron microscope (HITACHI S-3000N, Japan) operated 
at an accelerating voltage of 15 kV and a secondary detector. Freshly 
prepared nanocrystal suspensions were placed on a glass slide 
which was deposited on an SEM stub using double-sided tape.  
Particle size analysis 
Mean particle size and size distribution of the prepared nanocrystals 
was determined by using Malvern Zetasizer which follows the 
principle of laser light diffraction, also called Photon correlation 
spectroscopy. Prior to the measurement, the samples were 
appropriately diluted with water to a suitable scattering intensity 
and re-dispersed by sonication. 
Zeta potential 
The Zeta potential is a measure of the electric charge at the surface 
of the particles, indicating the physical stability of colloidal systems. 
The zeta potential values higher than 20mV indicate long-term 
electrostatic stability of aqueous dispersions. In this study, the Zeta 
Potential was assessed by determining the electrophoretic mobility 
of the particles using Malvern Zetasizer. 
X-ray diffraction analysis (XRD) 
XRD analysis was performed to study the effect of stabilizer on the 
crystallinity of lornoxicam. The XRD studies of the pure drug, LBCD, 
LPVP powder were carried out using X-ray diffractometer (XRD-
6000 diffractometer, Shimadzu, Japan). The samples were placed in 
a glass sample holder. Standard runs were taken using 40 kV 
voltage, 40 mA current and scanning rate of 0.02 °/min over a 2θ 
range of 5–50 °.  
Differential scanning calorimetry (DSC) 
DSC studies were performed to investigate the effect of surfactants, 
on the inner structure of lornoxicam and to confirm crystallinity 
result obtained by XRD. DSC studies were carried out using thermal 
analyzer (TA SDT-2790) which was calibrated for temperature and 
enthalpy with high purity standard indium. The samples were 
hermetically sealed in an aluminium pan and heated at a constant 
rate of 2 ⁰C/min over a temperature range of 0-300 ⁰C. The inert 
atmosphere was maintained by purging nitrogen gas at a flow of 50 
ml/min.  
Dissolution studies 
In vitro drug release of the samples was carried out using USP-type II 
dissolution apparatus (paddle type) (Electrolab TDT-08L). The 
paddle speed and temperature were set at 50 rpm and 37±0.5 °C, 
respectively. The volume of dissolution medium (0.1 N hydrochloric 
acid solutions and phosphate buffer solution, pH 6.8) was 
maintained as 900 ml. Aliquots of 5 ml samples were withdrawn at 
various intervals. The samples were filtered through a Whatman 
filter. The fresh dissolution medium (0.1 N hydrochloric acid 
solutions and phosphate buffer solution, pH 6.8) was replaced every 
time with the same quantity of the sample. Collected samples were 
analysed at λmax of drug (376 nm). The percentage cumulative drug 
release (% CDR) was calculated. The experiment was performed 
three times and the mean values were plotted versus time. 
Drug release kinetics 
To study the release kinetics, data obtained from in vitro drug 
release studies were plotted in various kinetics models to 
understand the linear relationship, i.e., kinetic principles. The data 
were processed for regression analysis using Ms Excel statistical 
functions. To study the release mechanisms, the data of in vitro drug 
release was verified using Higuchi’s model and Hixson Crowell Cube 
root law models. 
RESULTS AND DISCUSSION 
Preparation of lornoxicam nanocrystals 
Nanocrystals of lornoxicam were successfully prepared by 
precipitation method using two stabilisers. The obtained 
nanocrystals were assessed for size analysis and solid-state 
characterization by FTIR, XRD, DSC, and SEM analysis. 
FTIR study 
FTIR studies were conducted to confirm the identity of the drug in 
the form of a nanocrystal. Fig. 1 shows FTIR spectrum of pure 
lornoxicam with a characteristic peak at 3064.8 cm-1 due to 
stretching vibration of NH group. First sharp peak obtained at 1643 
cm-1 represent the stretching vibration of C=O in the structure of 
primary amide. Other peaks obtained at 1597 cm-1 shows the 
bending vibrations of N-H group in the secondary amide. Peak 
obtained at 1328 cm-1 is due to the stretching vibrations of O=S=O. 
Similarly, peak obtained at 788.9 cm-1 represent bending vibration of 
C-C1 [26]. Presence of all these groups in the sample shows 
similarity with actual drug structure which indicates the purity of 
drug substance. Peaks obtained from FTIR spectrum of powdered 
mixtures of LBCD, LPV nanocrystals shows no significant difference 
in peak intensities and wave numbers indicating nanoprecipitation 
process has any effect on drug stability. It can also be stated that 
selected stabilizers are not disturbing the identity of the drug 
without any chemical interaction with the surface of the stabilizer 
used. Hence, no effect of the selected stabilizers and nanonisation 
with the dried process were noticed in this study. 
The morphology of LOR nanoparticles  
Morphological study of the nanocrystals was examined by scanning 
electron microscopy (SEM). The SEM images were shown in fig. 2a 
and 2b. Lornoxicam nanocrystals with β CD showed rod-shaped 
particles (fig. 2a) whereas with PVP showed spherical particles (fig. 
2b) with a narrow PSD. Mostly particles were single without any 
aggregation. The average particle size for nanocrystals of lornoxicam 
was determined and the size was within the range of nanocrystals. 
Nanocrystals of lornoxicam with nano dimensions and spherical/rod 
shape are expected to be with improved solubility. 
Zeta sizer 
The mean particle size of the two nanoparticles LBCD, LPVP was 
found to be 137 nm and 278 nm respectively which indicate the 
formation of smaller particles than pure drug LOR, whose particles 
mean diameter was found to be 1010 nm, measured by trinocular 
microscopy (table 1). 
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Fig. 1: FTIR spectra of a) LOR b) LBCD c) LPVP 
 
  
Fig. 2a: SEM images of nanocrystals using ß-Cyclodextrin 
 
  
Fig. 2b: SEM images of nanocrystals using PVP-K30 
 
Table 1: Average particle size of lornoxicam nanocrystals 
Stabiliser Particle size (nm) mean±SD Zeta potential (mv) 
LPVP 137.2±28.4 -23.6 
LBCD 278.6±22.6 -24.5 
Lornoxicam 1010.0±47.2 - 
*Average of 100 particles, LBCD-lornoxicam nanocrystals using β CD, LPVP-lornoxicam nanocrystals using PVP 
 
Zeta potential 
Zeta potential of the LBCD, LPVP was found to be-24.5 mV (fig. 
3a),-23.6 mV (fig. 3b). Negative zeta potential is attributed to 
drug nanocrystals as stabilizers used provide steric stabilization 
(22). In general, zeta potential value of±20 mV is sufficient for 
the stability of nano suspension. The above values for 
nanocrystals, stabilized by steric stabilizers βCD, PVP-K 30 
indicates that the prepared formulations would not suffer from 
instability problems. 
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Fig. 3a: Zeta potential of lornoxicam nanocrystals prepared using ß-Cyclodextrin 
 
 
Fig. 3b: Zeta potential of lornoxicam nanocrystals prepared using PVP-K30 
 
X-ray diffraction pattern [XRD]  
According to many reports, there is a possibility that conversion of a 
drug to nanocrystal may decrease the degree of crystallinity of drug 
compounds or transform the drug crystals to its amorphous form. 
Therefore, it is significant to investigate the effect of the processes 
on the physical state of LBCD, LPVP. The solid powders were 
characterized by XRD. The patterns obtained of pure LOR, LBCD, 
LPVP were analyzed as shown in fig. 4. The diffraction peak of pure 
LOR exhibited several sharp high intensity peaks crystalline peaks at 
diffraction angles 2θ of 13.4 °, 14.26 °, 21.8 °, and 25.08 °, suggesting 
that it existed as a crystalline material. The LBCD, LPVP also showed 
the characteristic crystalline diffraction peaks at the same diffraction 
angles of pure LOR indicating no change in the crystalline state to 
amorphous state. However, the intensity of characteristic crystalline 
peaks was decreased revealing that the crystallinity of LBCD, LPVP 
was decreased a little. It can be assumed that better physicochemical 
properties observed such as; enhanced solubility and dissolution can 
be attributed to the particle size reduction and or influence of 
stabilizer and not to alterations in the crystalline state to amorphous 
state. Retaining crystalline state could be advantageous in terms of 
long-term stability. 
Differential scanning calorimetry [DSC]  
The DSC studies were performed to study the effect of nanosizing on 
solid state of lornoxicam. The DSC thermograms of LOR pure drug, 
LBCD, LPVP were shown in fig. 5a, b, c. The DSC thermogram of bulk 
LOR powder showed a sharp endothermic peak at 229.8 °C [2]. The 
thermogram of LBCD showed an endothermic peak at 221.5 °C and 
thermogram of LPVP showed an endothermic peak at 221.6. A slight 
but prominent shift in the peak of the drug was observed which may 
be due to the presence of the stabilizer. The crystallinity of the drug 
can be confirmed with the support from XRD data. Thus, the 
combined results from XRD and DSC studies show that nanosizing 
does not affect the crystallinity of lornoxicam. 
 
 
Fig. 4: PXRD of a) lornoxicam b) LBCD c) LPVP 
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Fig. 5a: Differential scanning calorimetry of lornoxicam-Heating rate (2 °C/min) 
 
 
Fig. 5b: Differential scanning calorimetry of LBCD 
 
 
Fig. 5c: Differential scanning calorimetry of LPVP 
 
Dissolution study in vitro drug release 
The drug release profiles of the two formulations have been 
performed in two different media i.e. 0.1 N HCl and phosphate 
buffer, pH 6.8 and were compared to study the drug release 
pattern at different time intervals. The profiles presented in fig. 
6a and 6b indicate the dissolution of pure as well as 
nanocrystals. The release was slow and % cumulative 
lornoxicam release was less and incomplete in acidic media. This 
could be due to slightly acidic nature of lornoxicam, with the pKa 
value of 4.7 [27], its solubility is pH dependent and it’s unable to 
dissolve completely under acidic conditions. With the increase of 
the pH of the dissolution medium to 6.8, the dissolution of the 
pure, as well as nanocrystals, has increased and complete 
dissolution was observed with nanocrystals. Though favorable 
pH condition was maintained for lornoxicam, the dissolution was 
still incomplete from pure drug owing to its larger size. Nano-
sized crystals displayed a dramatic increase in the extent of 
dissolution in comparison with pure LOR, especially during the 
initial stage. LBCD, LPVP exhibited 71.23 %, 57.05 % drug 
dissolution within 20 min whereas only 23.46 % of raw LOR 
dissolved during the same period. After 60 min, LBCD, LPVP 
were almost dissolved completely but only 37.35 % of raw LOR 
had dissolved owing to its crystalline nature and larger crystal 
size. This increase in the extent of dissolution of the drug from 
nanocrystals was distinctly superior compared to the plain drug, 
which might be attributed to reduction of the particle size, 
increase in the surface area thus improving saturation solubility 
of nanocrystals and showing complete dissolution within 
minutes. 
 
Fig. 6a: Dissolution profile of LOR, LBCD, LPVP in 0.1 N HCl 
(Results are expressed as mean, n=3) 
 
 
Fig. 6b: Dissolution profile of LOR, LBCD, LPVP in phosphate 
buffer solution, pH 6.8 (Results are expressed as mean, n=3) 
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Drug release kinetics 
Data obtained from in vitro drug release studies were plotted in various 
kinetics models for pure LOR, LBCD, and LPVP. Formulations showed 
higher R2 value (table 2) indicating first order drug release in both 0.1 N 
HCl and pH 6.8 phosphate buffer solution. Similarly, from the regression 
analysis using Ms Excel statistical functions for pure LOR and LBCD, 
LPVP formulations followed Higuchi’s model for release mechanisms. 
Though the lornoxicam release data indicated the Higuchi diffusion 
model it is difficult to reconcile the mechanism for an immediate release 
dosage form. Therefore, it was proposed to be the only dissolution rate 
limited mechanism (Hixson Crowell cube root law). 
 
Table 2: Comparison of drug kinetics and mechanisms of LOR, LBCD and LPVP formulations in phosphate buffer solution, pH 6.8 
Formulation Order/mechanism R2 Equation 
LBCD Zero 0.801 y = 1.5819x+24.526 
First 0.9443 y =-0.0327x+2.0984 
Higuchi 0.9441 y = 14.424x-0.5676 
Hixson Crowell cube root 0.4608 y =-0.0624x+2.6903 
LPVP Zero 0.894 y = 1.7549x+6.8494 
First 0.9887 y =-0.0231x+2.1068 
Higuchi 0.9274 y = 15.012x-16.498 
Hixson Crowell cube root 0.6236 y =-0.0744x+3.4044 
 
CONCLUSION 
In this study, nanocrystallisation technique was used to enhance the 
dissolution profile of the poorly soluble drug, lornoxicam. Antisolvent 
precipitation method was used using beta CD and PVP as stabilizers to 
inhibit particle growth and improve stability. Water was used as 
antisolvent. Nanocrystals of lornoxicam were successfully obtained 
with nano dimensions. The crystallinity of drug was confirmed by XRD 
analysis. SEM studies revealed the morphology of nanocrystals. 
Nanonisation improved the dissolution of the drug compared to pure 
form. Thus it can be stated that nanocrystal approach using antisolvent 
precipitation method is a simple and easy way to enhance the 
solubility of poorly soluble drugs.  
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